Devigili G
Divisione di Medicina, Ospedale S. Giovanni, Mezzolombardo, Trento.
Minerva Cardioangiol. 1994 Apr;42(4):177-89.
Calcium antagonists impede the entry of calcium into myocytes and inhibit myocardial contraction. Calcium antagonists differ in their relative negative inotropic potency and can provoke baroreceptor stimulation that modulates left ventricular (LV) performance. Calcium antagonists are uniformly well tolerated in patients with normal LV function. Use of these agents in patients with suspected LV function impairment has yielded results ranging from hemodynamic improvement to clinical deterioration and increased mortality. Although calcium antagonists are potent vasodilatators and produce short-term hemodynamic improvement, they are non use full as primary treatment in patients with congestive heart failure (CHF). They may have a place in the treatment of coexistent problems in patients with LV dysfunction. Short-term use of calcium antagonists for myocardial ischemia or severe hypertension is probably safe in the presence of LV dysfunction and overt CHF. Calcium antagonists appear to have a role in the treatment of patients with diastolic dysfunction of diverse etiologies.
钙拮抗剂可阻止钙进入心肌细胞并抑制心肌收缩。钙拮抗剂的相对负性肌力作用强度有所不同,且可激发压力感受器刺激,从而调节左心室(LV)功能。左心室功能正常的患者对钙拮抗剂普遍耐受性良好。在疑似左心室功能受损的患者中使用这些药物,结果从血流动力学改善到临床恶化及死亡率增加不等。尽管钙拮抗剂是强效血管扩张剂并能产生短期血流动力学改善,但它们作为充血性心力衰竭(CHF)患者的主要治疗方法并无用处。它们可能在治疗左心室功能障碍患者的并存问题中占有一席之地。在存在左心室功能障碍和明显CHF的情况下,短期使用钙拮抗剂治疗心肌缺血或重度高血压可能是安全的。钙拮抗剂似乎在治疗多种病因的舒张功能障碍患者中发挥作用。